Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jan;43(1):295-8.
doi: 10.1183/09031936.00140613. Epub 2013 Oct 17.

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial

Prescott G Woodruff  1 , Wissam Chatila, John E Connett, Gerard J Criner, Jeffrey L Curtis, Mark T Dransfield, Meilan K Han, Stephen C Lazarus, Nathaniel Marchetti, Thomas J Rogers, Paul D Scanlon, Don D Sin, Helen Voelker, Christine Wendt, Richard K Albert; COPD Clinical Research Network
Collaborators, Affiliations
Randomized Controlled Trial

Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial

Prescott G Woodruff et al. Eur Respir J. 2014 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

Figures

Figure 1
Figure 1
Effect of azithromycin on time to first exacerbation by change in soluble tumour necrosis factor-75 (sTNFR75) level at 3 months. 890 subjects had biomarker data at enrolment and at 3 months. a, b) Any decline in sTNFR75 levels between 0 and 3 months identified subjects in whom azithromycin was superior to placebo after 3 months. c, d) In subjects who did not manifest a decline in sTNFR75 levels, azithromycin was no better than placebo. Data are adjusted for centre. Findings persist while adjusting for centre and other potential confounders, e.g. age, sex, current smoking, oxygen use, inhaled corticosteroid use, forced expiratory volume in i1 s, bronchitis and compliance. Quartile 1: large decline in sTNFR75 at 3 months; quartile 2: moderate decline in sTNFR75 at 3 months; quartile 3: moderate increase in sTNFR75 at 3 months; quartile 4: large increase in sTNFR75 at 3 months. HR: hazard ratio.
See this image and copyright information in PMC

References

    1. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698. - PMC - PubMed
    1. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317–326. - PubMed
    1. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB. Ann Rheum Dis. 2000;59(Suppl. 1):i6–i16. - PMC - PubMed
    1. Hijdra D, Vorselaars AD, Gratters JC, et al. Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes. J Inflamm (Lond) 2012;9:38. - PMC - PubMed
    1. Aderka D, Engelmann H, Wysenbeek AJ, et al. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci. 1992;28:126–130. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources